SCHEDULE: T. Rowe Price Discloses 5.4% Stake in Guardant Health

T. Rowe Price Associates, Inc. has reported beneficial ownership of 5.4% of Guardant Health Inc.'s common stock as of March 31, 2026.

Summary

• T. Rowe Price Associates, Inc. has filed a Schedule 13G, indicating it beneficially owns 7,035,771 shares of Guardant Health Inc. common stock.
• This holding represents 5.4% of the total class of securities.
• The filing date for this event is March 31, 2026.
• T. Rowe Price Associates, Inc. is classified as an investment adviser.
• The company explicitly denies beneficial ownership for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It indicates a significant passive investment by a major asset manager, which can be positive for market perception, but it does not provide operational or financial performance updates for Guardant Health itself.

Positives

• T. Rowe Price Associates, Inc., a significant investment entity, has taken a notable stake in Guardant Health, potentially signaling confidence in the company's future prospects.
• The substantial shareholding of 5.4% suggests a material investment, which could lead to increased institutional interest and support for Guardant Health.

Negatives

• The filing is a Schedule 13G, which is an informational filing for passive investors, and does not indicate any active engagement or control-seeking behavior by T. Rowe Price Associates, Inc.

Risks

• While T. Rowe Price Associates, Inc. denies acquiring shares to influence control, any significant shift in their investment strategy or holdings could impact Guardant Health's stock price and market perception.
• The passive nature of the filing means T. Rowe Price is not actively involved in management or strategic direction, so any future changes in their investment thesis could lead to divestment without direct engagement with the company.

Future Outlook

The filing does not contain forward-looking statements or guidance from Guardant Health. It is a disclosure of T. Rowe Price Associates, Inc.'s current ownership stake.

Management Comments

• T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that a Schedule 13G filing by a major asset manager like T. Rowe Price Associates, Inc. often indicates a significant, albeit passive, investment in a company within the biotechnology or healthcare technology sector, such as Guardant Health, which is involved in precision oncology diagnostics.

Stakeholder Impact

• Shareholders: The filing may increase investor confidence due to the significant stake taken by a reputable asset manager, potentially influencing share price positively. However, the passive nature of the investment means no direct influence on company strategy.
• Employees: Continued investment by institutional players can signal stability and potential for growth, which may positively impact employee morale.
• Creditors: A stable or growing shareholder base can be seen as a positive indicator of the company's financial health and long-term viability.
• Suppliers and Customers: While not directly impacted, a stable and well-supported company is more likely to maintain consistent business relationships.

Next Steps

• T. Rowe Price Associates, Inc. will continue to hold its shares in Guardant Health, subject to its investment strategies.
• Guardant Health will continue its operations and business activities as usual, with T. Rowe Price Associates, Inc. as a significant passive shareholder.

Key Dates

Keywords

Guardant Health, T. Rowe Price Associates, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, Shareholder